Success Metrics

Clinical Success Rate

66.7%

Based on 2 completed trials

Completion Rate

67%(2/3)

Active Trials

1(25%)

Results Posted

150%(3 trials)

Terminated

1(25%)

Phase Distribution

Ph phase_2

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 2Efficacy & side effects

4(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(2)

Terminated(1)

Detailed Status

Completed2

Terminated1

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

66.7%

Most Advanced

Phase 2

Trials by Phase

Phase 24 (100.0%)

Trials by Status

terminated125%

completed250%

active_not_recruiting125%

Recent Activity

1 active trials

Showing 4 of 4

active_not_recruitingphase_2

Study to Evaluate the Safety and Feasibility of Diamyd® in Individuals at Risk for Type 1 Diabetes

NCT05683990

completedphase_2

Diamyd Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes

NCT03345004

completedphase_2

Diabetes Prevention - Immune Tolerance

NCT01122446

terminatedphase_2

Novel Therapy to Preserve Beta Cell Function in New Onset Type 1 Diabetes

NCT00837759

Clinical Trials (4)

Showing 4 of 4 trials

NCT05683990Phase 2

Study to Evaluate the Safety and Feasibility of Diamyd® in Individuals at Risk for Type 1 Diabetes

Active Not Recruiting

NCT03345004Phase 2

Diamyd Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes

Completed

NCT01122446Phase 2

Diabetes Prevention - Immune Tolerance

Completed

NCT00837759Phase 2

Novel Therapy to Preserve Beta Cell Function in New Onset Type 1 Diabetes

Terminated

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4